Re­gen­eron and Sanofi pull Lib­tayo app in cer­vi­cal can­cer, cit­ing post-mar­ket study dis­agree­ment with FDA

Sanofi and Re­gen­eron on Fri­day said they’ve de­cid­ed to pull their sBLA for their PD-1 Lib­tayo (cemi­plimab-rwlc) in sec­ond-line cer­vi­cal can­cer af­ter the com­pa­nies and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER